Reported 4 months ago
A proposal to use MDMA as a treatment for PTSD faced criticism as FDA advisers voted 10-1 against the drug's overall benefits, citing flawed study data and potential risks. The negative opinion could influence the FDA's decision in August. This setback impacts psychedelic advocates who hope to bring banned drugs like MDMA into mainstream medical use. The criticism focused on study flaws, lack of diversity in participants, and allegations of misconduct. This ruling could also affect financial investments in the psychedelic industry and the future review of other mind-altering drugs like LSD and psilocybin.
Source: YAHOO